Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies
TAMPA, FLORIDA & DUBLIN, IRELAND – March 25, 2020 – Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to ...
Read More
Read More
Vycellix Founders Awarded Major Swedish Grant to Establish NextGen-NK
Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners TAMPA, ...
Read More
Read More
Vycellix Announces Formation of Scientific Advisory Board
SAB Comprised of Key Opinion Leaders Advancing Next-Generation Cell & Gene-based Immuno-Oncology Therapeutic Platforms TAMPA, FLORIDA & STOCKHOLM, SWEDEN – June 25, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned ...
Read More
Read More
Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit
TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will present at the Innate Killer Summit 2019 to be held in ...
Read More
Read More
Cell & Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa
Vycellix is advancing pipeline of modulators and next-generation T cell & NK cell therapies for treatment of cancers Company to present on Cell Therapy Manufacturing Panel at Moffitt’s Business of Biotech Conference on Feb 22 TAMPA, FLORIDA & STOCKHOLM, SWEDEN ...
Read More
Read More
Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer
Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 – Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cellular therapies, ...
Read More
Read More
Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit
New Products Enhance Genetic Modification of Lymphocytes and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus ...
Read More
Read More
